PharmaEngine, Inc. (4162.TWO)
Taipei Exchange · TWD · Healthcare · Biotechnology
NT$55.70 (-0.36%) as of
Key statistics
- Market cap
- 8.00B
- P/E (TTM)
- 14.93
- Forward P/E
- 20.18
- EPS (TTM)
- 3.73
- Dividend yield
- 3.56%
- 52-week range
- 53.00 – 74.40
- Beta
- 0.11
- Revenue (TTM)
- 1.03B
- Profit margin
- 52.56%
- Volume
- 81.26k
About PharmaEngine, Inc.
PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is also developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Taipei, Taiwan
- Employees
- 45
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.